Johan H A Janssen,* David Henshaw†
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Kalgoorlie Regional Hospital, PO Box 8035, Hannans, Kalgoorlie, WA 6433.
Correspondence: Johan.Janssen@health.wa.gov.au
- 1. Hung J, for the Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention. Med J Aust 2003; 179: 147-152. <eMJA full text> <MJA full text>
- 2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71-86.
- 3. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
- 4. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
Online responses are no longer available. Please refer to our instructions for authors page for more information.